Xiya Cheng^1,#, Yunshu Ma^2,#, Jinglu Yan³, Yizhe Zhang², Riguge Su⁴, Xiaoming Tao^5,*, Jing Zhao^2,*, Peizhun Du^6,*

Oncology Research, Vol.34, No.10, 2026, DOI:10.32604/or.2026.083832 - 14 September 2026

Abstract Gastric cancer (GC) is a leading cause of cancer-related mortality worldwide. Accurate early detection, timely diagnostic stratification, and robust prognostic risk assessment are essential for optimizing clinical outcomes and improving survival duration. However, conventional serological biomarkers demonstrate limited diagnostic performance owing to suboptimal sensitivity and specificity, while standard chemotherapy and targeted therapies provide only modest survival benefits in GC. Marked inter- and intratumoral heterogeneity further characterizes GC as a biologically complex and treatment-resistant malignancy. To date, significant progress has been made in comprehensively delineating the complex molecular pathogenesis of GC, providing a strong rationale for More > Graphic Abstract

Shaohua Chen^1,#, Xiao Gan^1,#, Ping Lv^1,#, Qinggui Meng¹, Xiaocao Lin^1,2,*, Qingyun Zhang^1,2,*

Oncology Research, Vol.34, No.10, 2026, DOI:10.32604/or.2026.083704 - 14 September 2026

Abstract Background: While radical cystectomy is standard for muscle-invasive bladder cancer (MIBC), micrometastasis-related recurrence is common. Cisplatin-based neoadjuvant therapy (NAT) confers modest benefits, while immune checkpoint inhibitors (ICIs) provide new efficacy-enhancing strategies. This study aims to compare the efficacy and safety of ICIs with chemotherapy (NAC-ICI), neoadjuvant chemotherapy (NAC), and no neoadjuvant therapy (NNAT). It also explores potential biomarkers predictive of NAT response and evaluates the real-world efficacy of NAC-IC. Method: This single-center retrospective analysis included 80 radical cystectomy patients, with 51 NNAT group and 29 in the NAT group. Survival outcomes were evaluated by Kaplan-Meier survival… More >

Xiangui Liu^1,#, Jianhua Liu^2,#, Qingbin Meng^1,*, Yongsheng Shao¹

Oncology Research, Vol.34, No.10, 2026, DOI:10.32604/or.2026.082954 - 14 September 2026

Abstract Objectives: There is debate over the effect of sevoflurane (SEV) on different cancers. This study aims to explore SEV’s role in colon cancer (CC) progression. Methods: The CC cell lines were treated with SEV at concentrations of 1.7%, 3.4%, and 5.1%. Cell proliferation, apoptosis, migration, and invasion were assessed using Cell Counting Kit-8 (CCK-8), 5-ethynyl-2′-deoxyuridine (EdU) incorporation, colony formation assay, flow cytometry, Western blot, scratch assay, and Transwell assay. A xenograft tumor model was established to evaluate the effect of SEV in vivo. Expression levels of nuclear factor erythroid 2-related factor 2 (Nrf2), p62 (sequestosome-1), microtubule-associated protein… More > Graphic Abstract

Iseult M. Browne^1,2, Monica Esteban Garcia^1,2, Alicia F. C. Okines^1,2,*

Oncology Research, Vol.34, No.10, 2026, DOI:10.32604/or.2026.082829 - 14 September 2026

Abstract Triple negative breast cancer (TNBC) is defined by the absence of oestrogen receptor, progesterone receptor, and HER2 expression, and carries a disproportionate burden of breast cancer-related mortality due to its aggressive biology and historically limited therapeutic options. The treatment landscape of metastatic TNBC has undergone a fundamental transformation over the past decade, driven by immune checkpoint inhibitors, antibody-drug conjugates (ADCs), and the identification of actionable genomic alterations. This review provides a comprehensive, clinically oriented appraisal of the current and emerging therapeutic landscape of metastatic TNBC, encompassing its molecular underpinnings and tumour microenvironment biology. We critically More >

Qingqing Liu^1,2,#, Lei Li^3,4,#, Kumar Ganesan^1,2, Yang Jiang⁵, Kewu Zeng⁶, Yue Sui^1,2, Xinyuan Guan^2,7, Rongfang He^3,*, Jianping Chen^1,2,*

Oncology Research, Vol.34, No.10, 2026, DOI:10.32604/or.2026.082536 - 14 September 2026

Abstract Objectives: Sorting nexin 9 (SNX9) participates in endocytic trafficking and has been connected to several malignancies, but its involvement in breast cancer (BC) remains incompletely resolved. This work was designed to examine whether SNX9 supports BC progression and investigate signaling and cytoskeletal processes associated with its activity. Methods: The clinical relevance of SNX9 was assessed using bioinformatics analysis of publicly available cancer databases. Lentiviral vectors were used to establish BC cell models with stable SNX9 overexpression or knockdown. Both cellular (proliferation and motility) and murine (tumor growth and metastatic colonization) experiments were implemented to functionally characterize… More >

Yawan Zi^1,#, Huilin Yu^1,#, Xiaohui Wang¹, Yuezhou Zhang¹, Shengxin Fan¹, Jiukang Li², Jian Wang³, Ke Liao^1,*, Hong Chen^1,*

Oncology Research, Vol.34, No.10, 2026, DOI:10.32604/or.2026.082400 - 14 September 2026

Abstract Background: Although epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibition produces substantial initial benefit in EGFR-mutant non-small cell lung cancer, durable disease control is frequently compromised by the emergence of drug-resistant tumor cells. We therefore examined whether loss of cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) supports the resistant phenotype by altering redox control and the cellular threshold for ferroptotic injury. Methods: The Gene Expression Omnibus (GEO) datasets GSE172002 and GSE236654 were analyzed to identify resistance-associated pathways. cGAS was depleted in parental cells and restored in resistant derivatives, followed by phenotypic, redox, mitochondrial, and signaling assessments in… More >

Antonio David Lázaro-Sánchez^1,2,*, Javier David Benítez-Fuentes³, Sofía Wikström-Fernández⁴, María Nevado-Rodríguez⁵, Pablo Conesa-Zamora^2,6, Ginés Luengo-Gil^2,6, Alejandra Ivars-Rubio⁵, Marta Zafra-Poves⁵, Edgardo D. Carosella⁷, Belén Fernández-Molina⁸, Andrés Nieto-Olivares⁹, María José Sánchez de las Matas Garre¹⁰, Ana Belén Arroyo^2,6

Oncology Research, Vol.34, No.10, 2026, DOI:10.32604/or.2026.081674 - 14 September 2026

Abstract Background: Collecting duct carcinoma (CDC; Bellini duct carcinoma) is a rare, aggressive renal cancer with no established standard of care, and evidence for immune checkpoint inhibitor (ICI)-based therapy in CDC remains emerging and fragmented. We aimed to systematically synthesise efficacy and safety data on immunotherapy in adult patients with CDC. Methods: PubMed and Web of Science were searched from inception to 29 March 2025, with targeted post-search monitoring of key journals and ClinicalTrials.gov updated on 11 April 2026. Prospective interventional studies, observational cohorts/registries, and case series/reports were eligible. Screening, extraction and risk-of-bias appraisal (Joanna Briggs Institute… More >

Agata Kosmaczewska^*, Lidia Ciszak

Oncology Research, Vol.34, No.10, 2026, DOI:10.32604/or.2026.081365 - 14 September 2026

Abstract Chronic lymphocytic leukemia (CLL) is a biologically heterogeneous B cell malignancy in which non-malignant T lymphocytes constitute a critical component of the tumor microenvironment and significantly influence disease evolution and the therapeutic response. Growing evidence suggests that CLL-associated T cells not only participate in the antitumor response but also activate signals that promote the development of CLL subclones. Although novel targeted therapies, such as Bruton’s tyrosine kinase (BTK) inhibitors, BTK degraders, B-cell lymphoma 2 (BCL-2) inhibitors, T cell engagers, immune checkpoint inhibitors, and adoptive T cell therapy have different mechanisms of action, they affect the More > Graphic Abstract

Fiona Tsui-Fen Cheng^1,2,#, Kung-Ju Chen^3,#, Jing-Quan Zheng^3,4,5, Hui-Wen Chiu^3,6,7, Hui-Yu Lin^2,3,8,*, Yuan-Feng Lin^3,9,*

Oncology Research, Vol.34, No.10, 2026, DOI:10.32604/or.2026.081093 - 14 September 2026

Abstract Background: Metastatic dissemination of triple-negative breast cancer (TNBC) to distant organs, such as the lungs and brain, poses a significant threat to patient survival. Nevertheless, the molecular basis driving TNBC metastasis remains largely elusive. In the present study, we elucidated the role and underlying mechanism of OTU deubiquitinase 7B (OTUD7B) in promoting TNBC metastasis. Methods: The Cancer Genome Atlas (TCGA)/K-M Plotter databases were used for determining the prognostic significance of OTUD7B in TNBC patients. Cell migration and lung colony-forming assays were performed to evaluate the metastatic potential of TNBC cells. A cycloheximide-chase assay was employed to… More > Graphic Abstract

Shangjian Li¹, Qipeng Han², Xinying Sun³, Rongrong Yu^1,*

Oncology Research, Vol.34, No.10, 2026, DOI:10.32604/or.2026.080228 - 14 September 2026

Abstract Objective: Renal cell carcinoma is a common malignancy of the urinary system. In this study, we analyzed a public clear cell renal cell carcinoma (ccRCC) dataset and identified Nephrosis 2, idiopathic, steroid-resistant (NPHS2) as a candidate gene to investigate whether epigenetic dysregulation of NPHS2 is associated with tumor microenvironment remodeling. Methods: Differential expression analysis was first performed on GSE68417 using GEO2R. In addition, clinical samples and cell-based assays were used to evaluate changes in NPHS2 expression and promoter methylation following 5′-Aza-CdR treatment. Subsequently, 786-O and A498 cells were obtained, and sunitinib-resistant 786-O/R and A498/R sublines were… More >